Active Ingredient(s): Atoltivimab + Odesivimab + Maftivimab
FDA Approved: * October 14, 2020
Category: Antiviral

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".

Inmazeb Overview

Atoltivimab/maftivimab/odesivimab, developed as REGN-EB3 and sold under the brand name Inmazeb, is a fixed-dose combination of three monoclonal antibodies for the treatment of Zaire ebolavirus (Ebola virus).[2] It contains atoltivimab, maftivimab, and odesivimab-ebgn and was developed by Regeneron Pharmaceuticals.[2] The most common side effects include fever, chills, tachycardia (fast heart rate), tachypnea (fast breathing), and vomiting; however, these are al...

Read more Inmazeb Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source:

Recent Inmazeb Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

Atoltivimab + Odesivimab + Maftivimab
  • Solution: 16.7mg/1ml
Note: Above list includes dosages for all drugs with the same combination of active ingredients.

NDC Database Records for Inmazeb: (2 results)

Sorted by National Drug Code
  • 61755-018 Inmazeb Intravenous Injection, Solution by Regeneron Pharmaceuticals, Inc.
  • 61755-019 Inmazeb Intravenous Injection, Solution by Regeneron Pharmaceuticals, Inc.

Drugs with one or more similar ingredients: (1 result)